Change in High-Density Lipoprotein Cholesterol and Incident Coronary Heart Disease in Apparently Healthy Male Physicians

 This work was supported by the Office of Research and Development, Cooperative Studies Program (CSP), Department of Veterans Affairs. Dr. Djoussé is Principal Investigator on Grant K01 HL-70444 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland. The PHS is supported by Grants CA-34944, CA-40360, and CA-097193 from the National Cancer Institute and Grants HL-26490 and HL-34595 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland.

 The authors had full access to the data and take responsibility for its integrity, and all authors have read and agree to the manuscript as written. Dr. Bowman reports consulting for Veroscience LLC. Dr. Gaziano reports that he currently or in the past 5 years has received investigator-initiated federal funding from the National Institutes of Health (National Cancer Institute, National Heart, Lung, and Blood Institute, NIA, NEI) and the VA (CSP) and nonfederal investigator-initiated funding from McNeil Consumer Products and Pliva; research support in the form of pills and or packaging from BASF, DMS Pharmaceuticals, and Wyeth Pharmaceuticals; and honoria from Bayer and Pfizer for speaking engagements; and has served as a consultant for McNeil Consumer Products and Wyeth Pharmaceuticals; and as expert witness for Merck, Nutraquest, and Glaxo Smith Kline.

PII: S0002-9149(08)01389-1

doi:10.1016/j.amjcard.2008.07.055

Published by Elsevier Inc.